{"schema_version":"secwatch.filing_event.v1","accession":"0001549084-22-000048","form_type":"8-K","ticker":"CHRN","cik":"0001549084","company_name":"EKSO BIONICS HOLDINGS, INC.","filed_at":"2022-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.123403+00:00","generated_at":"2026-06-24T07:30:42.460760+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ekso Bionics Q2 revenue up 57% to $3.5M; net loss widens to $3.0M","bullets":["Revenue $3.5M (+57% YoY); EksoHealth $3.2M, EksoWorks $0.2M; 17 EksoNR units booked.","Net loss $3.0M ($0.23/share) vs $1.3M loss ($0.10) in Q2 2021; gross margin 47% vs 58%.","Received FDA 510(k) clearance for EksoNR for Multiple Sclerosis indication.","Cash $31.9M at June 30, 2022, down from $40.4M at Dec 31, 2021.","Gain on warrant revaluation $1.0M; R&D expense up 30% YoY on next-gen products."],"urls":{"canonical":"https://secwatch.observer/filing/0001549084-22-000048","json":"https://secwatch.observer/filing/0001549084-22-000048.json","markdown":"https://secwatch.observer/filing/0001549084-22-000048.md","text":"https://secwatch.observer/filing/0001549084-22-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549084/000154908422000048/0001549084-22-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549084/000154908422000048/ekso-20220728.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T07:30:42.460760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}